These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 874818)

  • 1. The pharmacology of verapamil. I. Elimination kinetics in dogs and correlation of plasma levels with effect on the eletrocardiogram.
    McAllister RG; Bourne DW; Dittert LW
    J Pharmacol Exp Ther; 1977 Jul; 202(1):38-44. PubMed ID: 874818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myocardial disposition and cardiac pharmacodynamics of verapamil in the dog.
    Keefe DL; Kates RE
    J Pharmacol Exp Ther; 1982 Jan; 220(1):91-6. PubMed ID: 7053427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aging alters verapamil elimination and dynamics: single dose and steady-state responses.
    Schwartz JB
    J Pharmacol Exp Ther; 1990 Oct; 255(1):364-73. PubMed ID: 2213568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of verapamil in man.
    Koike Y; Shimamura K; Shudo I; Saito H
    Res Commun Chem Pathol Pharmacol; 1979 Apr; 24(1):37-47. PubMed ID: 432439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of the enantiomers of verapamil in the dog.
    Bai SA; Lankford SM; Johnson LM
    Chirality; 1993; 5(6):436-42. PubMed ID: 8398603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacology of verapamil. III. Pharmacokinetics in normal subjects after intravenous drug administration.
    Dominic JA; Bourne DW; Tan TG; Kirsten EB; McAllister RG
    J Cardiovasc Pharmacol; 1981; 3(1):25-38. PubMed ID: 6160352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Verapamil pharmacodynamics and disposition in obese hypertensive patients.
    Abernethy DR; Schwartz JB
    J Cardiovasc Pharmacol; 1988 Feb; 11(2):209-15. PubMed ID: 2452316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concentration-time effects of quinidine disposition kinetics in rhesus monkeys.
    Ueda CT; Ballard B; Rowland M
    J Pharmacol Exp Ther; 1977 Mar; 200(3):459-68. PubMed ID: 403278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of verapamil on electrophysiologic properties of blood superfused cardiac Purkinje fibers.
    Danilo P; Hordof AJ; Reder RF; Rosen MR
    J Pharmacol Exp Ther; 1980 May; 213(2):222-7. PubMed ID: 7365685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Verapamil prolongs atrial fibrillation by evoking an intense sympathetic neurohumoral effect.
    Friedman HS; Rodney E; Sinha B; Sharafkhaneh A; Wattanasuwan N; Win M; Mallipeddi D; Sinha A; Hussain A; Dai CP
    J Investig Med; 1999 Jul; 47(6):293-303. PubMed ID: 10431484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate (SUN 1165), a new antiarrhythmic agent: effects on cardiac conduction.
    Hidaka T; Hamasaki S; Aisaka K; Ishihara T; Morita M; Toyama J; Yamada K
    Arzneimittelforschung; 1985; 35(9):1381-6. PubMed ID: 4084339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of hemodynamic changes on the elimination kinetics of verapamil and nifedipine.
    Hamann SR; Blouin RA; Chang SL; Kaltenborn KE; Tan TG; McAllister RG
    J Pharmacol Exp Ther; 1984 Nov; 231(2):301-5. PubMed ID: 6491984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the duration of infusion on the disposition of lidocaine in dogs.
    LeLorier J; Moisan R; Gagné J; Caillé G
    J Pharmacol Exp Ther; 1977 Dec; 203(3):507-11. PubMed ID: 925956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the pharmacokinetics and electrocardiographic effects of sublingual and intravenous verapamil.
    Berk SI; Beckman K; Hoon TJ; Hariman RJ; Hu D; Siegel FP; Bauman JL
    Pharmacotherapy; 1992; 12(1):33-9. PubMed ID: 1549537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent and time-dependent pharmacokinetics in the dog after intravenous administration of dextrorphan.
    Cleveland PA; Teller S; Kachevsky V; Pinili E; Evans R; Modi MW
    Drug Metab Dispos; 1991; 19(1):245-50. PubMed ID: 1673409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin.
    Fromm MF; Busse D; Kroemer HK; Eichelbaum M
    Hepatology; 1996 Oct; 24(4):796-801. PubMed ID: 8855178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bupivacaine accentuates the cardiovascular depressant effects of verapamil in conscious dogs.
    Edouard A; Froidevaux R; Berdeaux A; Ahmad R; Samii K; Noviant Y
    Eur J Anaesthesiol; 1987 Jul; 4(4):249-59. PubMed ID: 3653084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mannitol pharmacokinetics and serum osmolality in dogs and humans.
    Cloyd JC; Snyder BD; Cleeremans B; Bundlie SR; Blomquist CH; Lakatua DJ
    J Pharmacol Exp Ther; 1986 Feb; 236(2):301-6. PubMed ID: 3080582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor 2,2,2-trifluoro-1-(3-trimethylsilylphenyl) ethanone in dog. Potential for transdermal patch delivery.
    Dow J; Dulery BD; Hornsperger JM; Di Francesco GF; Keshary P; Haegele KD
    Arzneimittelforschung; 1995 Dec; 45(12):1245-52. PubMed ID: 8595078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of dantrolene and verapamil on atrioventricular conduction and cardiovascular performance in dogs.
    Lynch C; Durbin CG; Fisher NA; Veselis RA; Althaus JS
    Anesth Analg; 1986 Mar; 65(3):252-8. PubMed ID: 3954091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.